{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:34:10Z","timestamp":1792600450614,"version":"4.5.0"},"reference-count":52,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,12]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Low or nondetectable MRD pre-HCT leads to similar outcomes, suggesting that MRD negativity is not an absolute prerequisite for HCT. MRD post-HCT is more important than pre-HCT, and monitoring with sensitive techniques can detect very high-risk patients early.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000449","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T17:58:06Z","timestamp":1573581486000},"page":"3393-3405","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":99,"title":["More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4554-0265","authenticated-orcid":false,"given":"Peter","family":"Bader","sequence":"first","affiliation":[{"name":"Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Salzmann-Manrique","sequence":"additional","affiliation":[{"name":"Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5879-0610","authenticated-orcid":false,"given":"Adriana","family":"Balduzzi","sequence":"additional","affiliation":[{"name":"Clinica Pediatrica, Universit\u00e0 degli Studi di Milano-Bicocca, Ospedale San Gerardo, Monza, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Hugues","family":"Dalle","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hemato-Immunology, H\u00f4pital Robert Debr\u00e9 and Paris-Diderot University, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7222-3607","authenticated-orcid":false,"given":"Ann E.","family":"Woolfrey","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merav","family":"Bar","sequence":"additional","affiliation":[{"name":"Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7097-5917","authenticated-orcid":false,"given":"Michael R.","family":"Verneris","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Borowitz","sequence":"additional","affiliation":[{"name":"Department of Pathology, John Hopkins Medical Institutions, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research, National Cancer Center, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Gossai","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0101-4482","authenticated-orcid":false,"given":"Peter J.","family":"Shaw","sequence":"additional","affiliation":[{"name":"BMT Services, Sydney Children\u2019s Hospital Network, Westmead, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen R.","family":"Chen","sequence":"additional","affiliation":[{"name":"Pediatric Blood and Marrow Transplantation Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk R.","family":"Schultz","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology\/Bone Marrow Transplantation, Department of Pediatrics, British Columbia Children\u2019s Hospital, University of British Columbia, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3575-9175","authenticated-orcid":false,"given":"Hermann","family":"Kreyenberg","sequence":"additional","affiliation":[{"name":"Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Di Maio","sequence":"additional","affiliation":[{"name":"Clinica Pediatrica, Universit\u00e0 degli Studi di Milano-Bicocca, Ospedale San Gerardo, Monza, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2955-4528","authenticated-orcid":false,"given":"Gianni","family":"Cazzaniga","sequence":"additional","affiliation":[{"name":"Clinica Pediatrica, Universit\u00e0 degli Studi di Milano-Bicocca, Ospedale San Gerardo, Monza, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Eckert","sequence":"additional","affiliation":[{"name":"Charit\u00e9 University Medical Center Berlin, Children\u2019s Hospital, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9457-3763","authenticated-orcid":false,"given":"Vincent H. J.","family":"van der Velden","sequence":"additional","affiliation":[{"name":"Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0188-6005","authenticated-orcid":false,"given":"Rosemary","family":"Sutton","sequence":"additional","affiliation":[{"name":"School of Women\u2019s and Children\u2019s Health, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Randwick, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6703-2993","authenticated-orcid":false,"given":"Arjan","family":"Lankester","sequence":"additional","affiliation":[{"name":"Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Peters","sequence":"additional","affiliation":[{"name":"St Anna Children's Hospital, Universit\u00e4tsklinik f\u00fcr Kinder und Jugendheilkunde, Medizinische Universit\u00e4t Wien, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Klingebiel","sequence":"additional","affiliation":[{"name":"Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6798-8998","authenticated-orcid":false,"given":"Andre M.","family":"Willasch","sequence":"additional","affiliation":[{"name":"Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[{"name":"Pediatric Oncology, The Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-8420","authenticated-orcid":false,"given":"Michael A.","family":"Pulsipher","sequence":"additional","affiliation":[{"name":"Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,11,11]]},"reference":[{"issue":"9142","key":"2019111521541829500_B1","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(98)04058-6","article-title":"Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood","volume":"352","author":"van Dongen","year":"1998","journal-title":"Lancet"},{"issue":"suppl 1","key":"2019111521541829500_B2","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1016\/j.bbmt.2010.10.005","article-title":"High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant?","volume":"17","author":"Pulsipher","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111521541829500_B3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bbmt.2014.10.001","article-title":"Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111521541829500_B4","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1182\/blood.V92.11.4072","article-title":"Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia","volume":"92","author":"Knechtli","year":"1998","journal-title":"Blood"},{"issue":"9","key":"2019111521541829500_B5","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/sj.leu.2402552","article-title":"Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL","volume":"16","author":"Bader","year":"2002","journal-title":"Leukemia"},{"issue":"3","key":"2019111521541829500_B6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group","volume":"27","author":"Bader","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111521541829500_B7","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/sj.leu.2402198","article-title":"Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia","volume":"15","author":"van der Velden","year":"2001","journal-title":"Leukemia"},{"issue":"8","key":"2019111521541829500_B8","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/leu.2010.133","article-title":"Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation","volume":"24","author":"Lankester","year":"2010","journal-title":"Leukemia"},{"issue":"22","key":"2019111521541829500_B9","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","article-title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2019111521541829500_B10","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2014.58.4631","article-title":"Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial","volume":"33","author":"Bader","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111521541829500_B11","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1046\/j.1365-2141.1998.00873.x","article-title":"Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia","volume":"102","author":"Knechtli","year":"1998","journal-title":"Br J Haematol"},{"issue":"13","key":"2019111521541829500_B12","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1182\/blood-2013-10-534297","article-title":"The addition of sirolimus to tacrolimus\/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children\u2019s Oncology Group\/Pediatric Blood and Marrow Transplant Consortium trial","volume":"123","author":"Pulsipher","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111521541829500_B13","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bbmt.2013.07.006","article-title":"Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group","volume":"19","author":"Schultz","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111521541829500_B14","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia"},{"key":"2019111521541829500_B15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-1-59745-418-6_7","article-title":"MRD detection in acute lymphoblastic leukemia patients using Ig\/TCR gene rearrangements as targets for real-time quantitative PCR","volume":"538","author":"van der Velden","year":"2009","journal-title":"Methods Mol Biol"},{"issue":"4","key":"2019111521541829500_B16","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"issue":"8","key":"2019111521541829500_B17","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children\u2019s Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2019111521541829500_B18","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood.V99.6.1952","article-title":"Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia","volume":"99","author":"Dworzak","year":"2002","journal-title":"Blood"},{"issue":"8","key":"2019111521541829500_B19","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/sj.leu.2403001","article-title":"Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children\u2019s Oncology Group study","volume":"17","author":"Borowitz","year":"2003","journal-title":"Leukemia"},{"issue":"6","key":"2019111521541829500_B20","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1365-2141.2005.05401.x","article-title":"Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR","volume":"128","author":"Kerst","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111521541829500_B21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"2019111521541829500_B22","doi-asserted-by":"crossref","DOI":"10.1002\/9781118032985","volume-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"2002","edition":"2nd ed"},{"issue":"3","key":"2019111521541829500_B23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/biomet\/69.3.553","article-title":"A class of rank test procedures for censored survival data","volume":"69","author":"Huntington","year":"1982","journal-title":"Biometrika"},{"issue":"3","key":"2019111521541829500_B24","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"2019111521541829500_B25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B"},{"key":"2019111521541829500_B26","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"2019111521541829500_B27","article-title":"The Concordance Statistic and the Cox Mode","volume-title":"Technical Report 85","author":"Therneau","year":"2017"},{"key":"2019111521541829500_B28","volume-title":"Regression Modeling Strategies","author":"Harrell","year":"2006"},{"issue":"11","key":"2019111521541829500_B29","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111521541829500_B30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/biostatistics\/kxr032","article-title":"Competing risks regression for clustered data","volume":"13","author":"Zhou","year":"2012","journal-title":"Biostatistics"},{"issue":"22","key":"2019111521541829500_B31","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1002\/sim.6994","article-title":"Developing points-based risk-scoring systems in the presence of competing risks [published correction appears in Stat Med. 2018;37(8):1405]","volume":"35","author":"Austin","year":"2016","journal-title":"Stat Med"},{"key":"2019111521541829500_B32","doi-asserted-by":"crossref","DOI":"10.1093\/biostatistics\/kxt059","volume-title":"Concordance for Prognostic Model with Competing Risks","author":"Wolbers","year":"2014"},{"issue":"4","key":"2019111521541829500_B33","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/EDE.0b013e3181a39056","article-title":"Prognostic models with competing risks: methods and application to coronary risk prediction","volume":"20","author":"Wolbers","year":"2009","journal-title":"Epidemiology"},{"key":"2019111521541829500_B34","volume-title":"The R Foundation for Statistical Computing c\/o Institut f\u00fcr Statistik und Wahrscheinlichkeitstheorie der Technischen Universit\u00e4t Wien: R, a language and environment for statistical computing and graphics (Version 3.3.3)","author":"R-Core-Team","year":"2017"},{"issue":"suppl 2","key":"2019111521541829500_B35","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1038\/bmt.2008.58","article-title":"Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials","volume":"41","author":"Schrauder","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2019111521541829500_B36","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"2019111521541829500_B37","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2141.2003.04394.x","article-title":"Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia","volume":"122","author":"Goulden","year":"2003","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111521541829500_B38","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bjh.12639","article-title":"Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?","volume":"164","author":"Balduzzi","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111521541829500_B39","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/bjh.15086","article-title":"Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia","volume":"180","author":"Lovisa","year":"2018","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111521541829500_B40","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.2004.05.198","article-title":"Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?","volume":"22","author":"Bader","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111521541829500_B41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbmt.2016.10.006","article-title":"Pre-emptive immunotherapy for clearance of molecular disease in childhood acute lymphoblastic leukemia after transplantation","volume":"23","author":"Rettinger","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2019111521541829500_B42","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1016\/S2352-3026(15)00147-7","article-title":"Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study","volume":"2","author":"Anderlini","year":"2015","journal-title":"Lancet Haematol"},{"issue":"8","key":"2019111521541829500_B43","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/bmt.2013.19","article-title":"Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation","volume":"48","author":"Rettinger","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2019111521541829500_B44","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3324\/haematol.11132","article-title":"Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study","volume":"92","author":"Introna","year":"2007","journal-title":"Haematologica"},{"issue":"1-2","key":"2019111521541829500_B45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.imlet.2013.09.017","article-title":"Cytokine induced killer (CIK) cells for the treatment of haematological neoplasms","volume":"155","author":"Introna","year":"2013","journal-title":"Immunol Lett"},{"issue":"8","key":"2019111521541829500_B46","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"18","key":"2019111521541829500_B47","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111521541829500_B48","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"95","key":"2019111521541829500_B49","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"9967","key":"2019111521541829500_B50","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"2019111521541829500_B51","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/bmt.2015.103","article-title":"Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?","volume":"50","author":"Pulsipher","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2019111521541829500_B52","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2001-11-0059","article-title":"Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome","volume":"100","author":"Zecca","year":"2002","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/21\/3393\/1506192\/advancesadv2019000449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/21\/3393\/1506192\/advancesadv2019000449.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T20:27:01Z","timestamp":1722025621000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/21\/3393\/422754\/More-precisely-defining-risk-periHCT-in-pediatric"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,11]]},"references-count":52,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2019,11,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000449","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,11]]}}}